CCT2 regulates the proliferation, apoptosis, and cell cycle arrest of multiple myeloma cells through the P53 signalling pathway Authors: Hongxiu Wang, Xiaomin Chen, Yang Liu, Siqi Wang, Qiuyu Xiang, Yu Zhao, Lixiu Luo, Yanling Wu, Chunlan Huang Published: 2026 ABSTRACT Multiple myeloma (MM) is the second most common malignant tumor of the hematologic system, characterized by a high relapse rate and difficulty in achieving a cure. Elucidating the underlying molecular mechanisms driving MM progression is crucial for identifying new therapeutic targets. This study focuses on the molecule CCT2 (Chaperonin Containing TCP1 Subunit 2) to reveal its regulatory role and associated signaling pathway features in the malignant progression of MM. Bioinformatics analyses were used for preliminary screening; correlation analyses with clinical samples assessed its diagnostic value; RT-qPCR and western blot techniques measured expression levels; lentiviral transfection was employed for gene manipulation; CCK8 assays and flow cytometry analyzed cellular behavior; additionally, a subcutaneous xenograft model in nude mice was established for in vivo validation. CCT2 expression was significantly upregulated in the MM patient cohort. Clinical data analysis showed a positive correlation between CCT2 expression and plasma cell proportion, and a negative correlation with patient survival. Functional studies confirmed that CCT2 promotes tumor growth. Knockdown of CCT2 expression via gene silencing markedly activated the p53 signaling pathway, induced apoptosis in MM cells, and caused cell cycle arrest, ultimately inhibiting proliferative capacity. Downregulation of CCT2 effectively activates the p53 signaling pathway, primarily by promoting apoptosis and inducing cell cycle arrest in MM cells, thereby exerting a negative regulatory effect on cell proliferation.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-51083-z. Introduction Multiple myeloma (MM) is a malignant hematologic tumor originating from bone marrow plasma cells. Abnormal plasma cells proliferate within the bone marrow and continuously accumulate, leading to clinical manifestations such as bone destruction, anemia, and renal dysfunction1–4. Although significant breakthroughs have been made in chemotherapy and immunotherapy, and progress has been achieved in targeted treatment strategies5–8, curing this disease remains highly challenging. The molecular mechanisms involved in the progression of MM need to be elucidated urgently, which will provide a critical theoretical foundation for establishing novel therapeutic targets. As one of the components of the molecular chaperone protein complex (Chaperonin Containing TCP-1, abbreviated as the TRiC complex), the functional characteristics of the CCT2 subunit (Chaperonin Containing TCP1 Subunit 2) have been elucidated. This protein primarily plays a role in critical biological processes such as protein folding, assembly, and degradation9–12. Previous studies have shown that the expression level of CCT2 is significantly upregulated in various malignant tumor tissues, including breast cancer, hepatocellular carcinoma, and prostate cancer13–15. This indicates a clear association between CCT2 and tumor cell proliferation capacity, regulation of apoptosis, cell cycle changes, and the development of drug resistance16, 17. However, its specific role and mechanism in multiple myeloma (MM) cells have not yet been investigated. Among the many tumor suppressor mechanisms within cells, the importance of the P53 signaling pathway ranks at the forefront18. In multiple myeloma (MM), P53 holds a significant position, as it is associated with the occurrence, treatment, and prognosis of MM19. DNA damage arises from external stimuli, leading to the activation of ATM and ATR, which in turn catalyze the phosphorylation of the kinases CHEK1 and CHEK220–22. Meanwhile, the activation of P53 can initiate the apoptosis program by upregulating the expression of apoptotic genes, subsequently activating Caspase-3 and Caspase-9, ultimately triggering cell apoptosis and thereby inhibiting tumor development22. However, whether CCT2’s regulatory role in MM growth involves the P53 signaling pathway remains unknown. This study aims to investigate the role of CCT2 in multiple myeloma (MM), focusing on the regulation of MM cell proliferation, apoptosis, and cell cycle by CCT2. It proposes that CCT2 may regulate MM cell growth through the p53 signaling pathway, which could provide a new therapeutic target for MM and offer novel research ideas and theoretical support for future MM treatments. Materials and methods Bioinformatics analysis RNA sequencing data and related clinical prognosis information for 786 multiple myeloma (MM) patients were obtained from the MMRF CoMMpass database (https://portal.gdc.cancer.gov/). After excluding 71 patients who died from non-tumor-related causes, a total of 716 patients were included in the analysis. Expression data were transformed using log2(TPM + 1), and quantile normalization was performed using the normalizeBetweenArrays function from the limma package (version 3.62.2) to correct for technical biases between samples. All data processing and visualization were conducted in R software (version 4.4.3). The timeROC package (version 0.4) was used to calculate the area under the curve (AUC) for survival status at 1, 3, and 5 years, and corresponding ROC curves were plotted for these time points. Survival rates for the two patient groups were estimated using the Kaplan-Meier method. Clinical specimens This study recruited 32 newly diagnosed multiple myeloma (MM) patients and 14 healthy individuals. They received MM treatment at the Affiliated Hospital of Southwest Medical University between March 2024 and September 2025. All patients were diagnosed with newly symptomatic MM according to the International Myeloma Working Group criteria. None of the patients had undergone radiotherapy or chemotherapy prior to sampling. Additionally, these patients had no other hematologic malignancies or solid tumors.All experiments involving human samples in this study were approved by the Institutional Review Board of the Affiliated Hospital of Southwest Medical University (Approval No. KY2024363) (see Supplementary Document 1 for details). Written informed consent was obtained from all participants prior to their involvement in the research. Furthermore, all studies were conducted in accordance with relevant ethical guidelines and regulations. All experiments were carried out following the applicable guidelines and regulations. Cell sorting and cell culture The multiple myeloma (MM) cell line RPMI-8226 was purchased from Procell Company (Wuhan, China), while NCI-H929 and MM.1 S were obtained from FUHENG BIOLOGY (Shanghai, China). All cells were cultured in RPMI-1640 medium purchased from Thermo Fisher Scientific (Wuhan, China) and maintained in a humidified incubator at 37 °C with 5% carbon dioxide. Bone marrow plasma cells were isolated from bone marrow samples of MM patients and healthy bone marrow donors. The samples were processed by density gradient centrifugation (400×g, 30 min, 22 °C) to separate mononuclear cells. Plasma cells were then sorted from the bone marrow mononuclear cells using CD138-coated magnetic beads purchased from STEMCELL (Vancouver, Canada)23. The isolated plasma cells were stored at -80 °C for subsequent analyses. Lentiviral transduction According to the experimental protocol, we knocked down/overexpressed CCT2 using CCT2-specific short hairpin RNA (shRNA) vectors, CCT2 overexpression vectors (LV-CCT2), and empty vectors designed by Shanghai GeneChem Co., Ltd. (Shanghai, China). Lentiviruses carrying the CCT2-shRNA/LV-CCT2 vectors and control vectors were separately transduced into RPMI-8226, NCI-H929, and MM.1 S cells (MOI = 80). Stable transduced cells were selected using puromycin (2 µg/mL). Cell proliferation assay We will select stable transfected cells using puromycin and seed 8,000 cells per well in a 96-well plate. These cells are cultured in complete RPMI-1640 medium. According to the manufacturer’s instructions, the absorbance of samples at 24, 48, and 72 h was measured at 450 nm using the APE-BIO Cell Counting Kit-8 (Houston, USA). Flow cytometry apoptosis assay Using the Sigma PE/7-AAD Apoptosis Detection Kit (Missouri, USA), detection was performed with a BD FACSCalibur flow cytometer (New Jersey, USA), and analysis was conducted using FlowJo 10.0 software. PE+ staining indicates early apoptotic cells, while PE + 7-AAD+ staining indicates late apoptotic cells. Cell cycle analysis Cell cycle analysis was performed using the GeneCopoeia cell cycle detection kit (Guangzhou, China) and a BD FACSCalibur flow cytometer. Western blot analysis Total protein was extracted using Lambrolide RIPA lysis buffer and Protease Inhibitor Cocktail (Shanghai, China). Equal amounts of protein lysates were separated on 10% Genefist SDS-PAGE gels and transferred onto polyvinylidene fluoride (PVDF) membranes (Guangzhou, China). After blocking and antibody incubation (antibody details in Supplementary File 1), signals were generated using Biyuntian Ji Super Sensitive ECL solution (Shanghai, China) and detected with the Touch Imager Pro electronic clamping imaging system (California, USA) (full Western blot membranes are shown in Supplementary File 3). RT-qPCR Total RNA was extracted from cells using the SteadyPure Rapid RNA Extraction Kit (Aikery Bio, Nanjing, China). cDNA was synthesized using the HiScript III All-in-one RT SuperMix (Vazyme). qRT-PCR was performed using ChamQ Universal SYBR qPCR Master Mix (Nanjing, China) on a QuantStudio 3 real-time PCR system, with GAPDH as the normalization control (primer sequences are provided in Supplementary File 2). Data analysis was conducted using QuantStudio Design and Analysis Software (Comparative Ct with Melt Fast) and Microsoft Excel 2021. Immunohistochemistry Fresh tumor tissue was embedded in paraffin and sectioned, then baked overnight at 60 °C. The sections were soaked in fresh xylene three times, 10 min each time, until the background around the sections was clear and transparent. The sections were washed with a graded alcohol series of 100%, 95%, and 75%. Then, the sections were placed in antigen retrieval solution and heated on high for 5 min, followed by cooling for 10 min (repeated 2–3 times) to enhance antigen exposure. Endogenous peroxidase was inactivated. Abcam CD138 antibody (Cambridge, UK) was added and incubated overnight at 4 °C. The primary antibody was discarded, sections were washed, then secondary antibody was added and incubated at 37 °C for 20 min. DAB staining, differentiation, hematoxylin counterstaining, and dehydration were performed. Finally, neutral resin was applied to mount the slides, which were then observed and photographed under a microscope. MM xenograft subcutaneous tumour animal model The Animal Research Ethics Committee of Southwest Medical University reviewed and approved the animal study (Approval No. 20250509-001, see Supplementary Document 2 for details). Strictly following the ARRIVE guidelines, nude mice weighing between 18.1 g and 19.2 g were selected. Using a randomized method, animals were “randomly” chosen from cages and divided into experimental and control groups, with 5 mice in each group. After selection, the control group weighed between 18.2 g and 19.2 g, and the experimental group weighed between 18.1 g and 19.0 g; there was no statistically significant difference in weight between the two groups. All mice were housed in the SPF-level animal facility at Southwest Medical University. A total of 1 × 107 control or CCT2-overexpressing RPMI-8226 cells were subcutaneously injected approximately 1 cm below the right scapula of each nude mouse. Tumor growth volume and general condition of the mice were regularly monitored. Tumor volume (V) was calculated using the formula V = (L×W²) / 2, where L is the longest diameter and W is the shortest diameter. Tumor size and volume were confirmed to remain within ethical limits. After 28 days, the mice were euthanized. Based on their body weight, mice were anesthetized with pentobarbital sodium and then euthanized by cervical dislocation. Tumors were excised, weighed, measured for volume, and prepared for subsequent analyses. Statistical analysis Each experiment was performed three times. Statistical analysis was conducted using SPSS 20.0 software or GraphPad Prism 9.3 software. Data with a normal distribution are presented as mean ± standard deviation (SD), while data not normally distributed are expressed as interquartile range (IQR). Independent samples t-test was used for data with normal distribution, and the Mann-Whitney U test was applied for data that did not meet normality. Pearson’s linear regression analysis was used to determine correlations. The log-rank test was employed to compare Kaplan-Meier survival curves. All graphing and statistical analyses were performed using GraphPad Prism 9.3 (GraphPad Software, Inc.). A p-value of less than 0.05 was considered statistically significant (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Results CCT2 is upregulated in multiple myeloma and predicts poor prognosis Through bioinformatics analysis of the correlation between CCT2 and multiple myeloma (MM), it was found that the CCT2 gene and protein are significantly overexpressed in MM patients and are associated with the prognosis and survival of MM patients (Fig. 1A). To further confirm the clinical significance of CCT2 expression in MM patients, we collected clinical data and examined CCT2 expression in bone marrow plasma cells from newly diagnosed MM patients and healthy controls using RT-qPCR and Western blotting with a CCT2 antibody. The expression level of CCT2 in plasma cells from MM patients was significantly higher than that in normal controls (Fig. 1B and C), and CCT2 expression was positively correlated with the proportion of plasma cells (Fig. 1D). These results indicate that CCT2 is upregulated in MM patients and may serve as a predictive factor for MM survival and relapse. Fig. 1Upregulation of CCT2 is associated with poor prognosis in MM patients. (A) CCT2 gene is upregulated in MM and negatively correlated with prognosis; (B) CCT2 mRNA is upregulated in bone marrow plasma cells of newly diagnosed MM; (C) CCT2 protein is upregulated in bone marrow plasma cells of newly diagnosed MM (original western blot membranes are shown in Supplementary Document 3); (D) CCT2 is positively correlated with the proportion of plasma cells in MM patients. (** P < 0.01) Upregulation of CCT2 is associated with poor prognosis in MM patients. (A) CCT2 gene is upregulated in MM and negatively correlated with prognosis; (B) CCT2 mRNA is upregulated in bone marrow plasma cells of newly diagnosed MM; (C) CCT2 protein is upregulated in bone marrow plasma cells of newly diagnosed MM (original western blot membranes are shown in Supplementary Document 3); (D) CCT2 is positively correlated with the proportion of plasma cells in MM patients. (** P < 0.01) CCT2 enhances MM cell proliferation in vitro and in vivo Before functional testing, we examined the expression levels of CCT2 mRNA in different human multiple myeloma (MM) cell lines. Compared to normal plasma cells, NCI-H929 showed the highest expression level, followed by RPMI-8226, with MM.1 S having the lowest expression (Fig. 2A). Next, we performed lentiviral transduction of sh-CCT2 in RPMI-8226 and NCI-H929 cells, and overexpressed CCT2 in RPMI-8226 and MM.1 S cells. Successful construction of LV-CCT2 and sh-CCT2 was confirmed by RT-qPCR and Western blotting (Fig. 2B and C). In the CCK8 proliferation assay, MM cells with CCT2 knockdown showed significantly reduced proliferation compared to the sh-NC group (Fig. 2D), whereas MM cells overexpressing CCT2 exhibited markedly enhanced proliferation (Fig. 2E). In vivo experiments revealed that upregulation of CCT2 in MM cells significantly promoted subcutaneous tumor growth in mice (Fig. 2F), with the largest tumor in the LV-CCT2 group measuring 1.06 cm in length and 1.02 cm in width, compared to 0.79 cm by 0.78 cm in the control group. Western blot analysis of proteins extracted from mouse tumors indicated a significant downregulation of P53 protein in the CCT2 overexpression group (Fig. 2G). Subcutaneous tumors were subjected to CD138 immunohistochemistry and H&E staining, confirming them as multiple myeloma tumors (Fig. 2H). Ki67 staining to assess proliferation showed that the high CCT2 expression group had significantly increased proliferative capacity (Fig. 2H). These data indicate that downregulation of CCT2 can inhibit the proliferation of MM cells. Fig. 2CCT2 promotes MM cell proliferation both in vitro and in vivo. (A) Comparison of CCT2 mRNA levels in three human MM cell lines, with the lowest expression in MM.1 S and the highest in NCI-H929. (B, C) Validation of successful CCT2 knockdown/overexpression at the gene and protein levels (original western blot membranes are shown in Supplementary Document 4). (D) Knockdown inhibits MM cell proliferation as measured by CCK8 assay. (E) Overexpression of CCT2 promotes MM cell proliferation. (F) Subcutaneous tumor formation in nude mice confirms that CCT2 promotes MM growth, with the largest tumor volume in the LV-CCT2 group reaching 0.55 cm³ compared to 0.24 cm³ in the control group. (G) Western blot (original membranes in Supplementary Document 5) and mRNA analysis of CCT2 and P53 proteins in subcutaneous tumors from nude mice. (H) CD138 immunohistochemical staining (positive staining appears brownish-yellow, localized to the cell membrane) and HE staining confirm tumor morphology; Ki67 staining indicates that the proliferation rate in the LV-CCT2 group is significantly higher than in the control group (* P < 0.05, ** P < 0.01, **** P < 0.0001). CCT2 promotes MM cell proliferation both in vitro and in vivo. (A) Comparison of CCT2 mRNA levels in three human MM cell lines, with the lowest expression in MM.1 S and the highest in NCI-H929. (B, C) Validation of successful CCT2 knockdown/overexpression at the gene and protein levels (original western blot membranes are shown in Supplementary Document 4). (D) Knockdown inhibits MM cell proliferation as measured by CCK8 assay. (E) Overexpression of CCT2 promotes MM cell proliferation. (F) Subcutaneous tumor formation in nude mice confirms that CCT2 promotes MM growth, with the largest tumor volume in the LV-CCT2 group reaching 0.55 cm³ compared to 0.24 cm³ in the control group. (G) Western blot (original membranes in Supplementary Document 5) and mRNA analysis of CCT2 and P53 proteins in subcutaneous tumors from nude mice. (H) CD138 immunohistochemical staining (positive staining appears brownish-yellow, localized to the cell membrane) and HE staining confirm tumor morphology; Ki67 staining indicates that the proliferation rate in the LV-CCT2 group is significantly higher than in the control group (* P < 0.05, ** P < 0.01, **** P < 0.0001). CCT2 promotes cell cycle arrest and induces apoptosis in MM cells Multiple myeloma (MM) cells with knocked-down or overexpressed CCT2 were analyzed by apoptosis assays, indicating that downregulation of CCT2 promotes MM cell apoptosis (Fig. 3A), while upregulation of CCT2 reduces MM cell apoptosis (Fig. 3B). Cell cycle analysis by flow cytometry showed that CCT2 downregulation in MM cells weakened the G1/S transition, causing cell cycle arrest in the G1 phase (Fig. 3C); conversely, CCT2 upregulation enhanced the transition (Fig. 3D). These results suggest that CCT2 controls MM cell growth by regulating the cell cycle and apoptosis. Fig. 3Knockdown of CCT2 promotes cell cycle arrest and apoptosis in MM cells. (A) Apoptosis increases in MM cells with CCT2 knockdown. (B) Apoptosis decreases in cells overexpressing CCT2. (C) MM cells with CCT2 knockdown are mainly arrested in the G1 phase. (D) Overexpression of CCT2 reduces the G1 phase population. (* P < 0.05, ** P < 0.01, **** P < 0.0001) Knockdown of CCT2 promotes cell cycle arrest and apoptosis in MM cells. (A) Apoptosis increases in MM cells with CCT2 knockdown. (B) Apoptosis decreases in cells overexpressing CCT2. (C) MM cells with CCT2 knockdown are mainly arrested in the G1 phase. (D) Overexpression of CCT2 reduces the G1 phase population. (* P < 0.05, ** P < 0.01, **** P < 0.0001) CCT2 regulates MM cell growth by activating the P53 signalling pathway Given the significant impact of CCT2 on MM cell proliferation, apoptosis, and cell cycle regulation, we investigated the relationship between CCT2 and signaling pathways that regulate tumor growth. Our research group previously conducted gene set enrichment analysis (GSEA) on CCT2-related differential genes in MM and found that CCT2 is associated with the p53 pathway in multiple myeloma (Supplementary Document 6). Previous studies have shown that CCT2 participates in the folding and stability regulation of the p53 protein24–26. Both the NCCN guidelines and IMWG consensus emphasize that p53 abnormalities are important prognostic factors in multiple myeloma and play a critical role in MM risk stratification27–29. Additionally, Preliminary clinical sample experiments from the research group suggest that P53 protein is downregulated in newly diagnosed multiple myeloma (MM) patients (Fig. 4A). Therefore, we hypothesized that CCT2 may regulate MM proliferation through the p53 signaling pathway.To test this, we examined pathway gene and protein expression levels in MM cells with CCT2 knockdown. We observed decreased expression of BCL-2, MDM2, Cyclin E, and CDK2, while mRNA and protein levels of TP53, BAX, FAS, Caspase 3, CHEK1, and P21 were increased. Conversely, in the CCT2 overexpression group, the opposite results were seen (Fig. 4B and C). To verify whether CCT2 regulates MM cell growth via the p53 pathway, we treated CCT2-knockdown MM cells with the p53 inhibitor Pifithrin-α hydrobromide (PFT-α), purchased from MedChemExpress (MCE) (Zhejiang, China). After treatment, MM cell proliferation increased (Fig. 5A), apoptosis decreased (Fig. 5B), the proportion of cells arrested in G1 phase decreased (Fig. 5C), and BAX and CHK1 were downregulated while BCL-2 and CDK2 were upregulated (Fig. 5D and E).We conclude that CCT2 mediates MM growth by negatively regulating the p53 signaling pathway, thereby modulating apoptosis and cell cycle arrest (Fig. 5F). Fig. 4Detection of P53 pathway genes and protein levels. (A) Expression of TP53 in newly diagnosed MM patients (original western blot membranes are shown in Supplementary Document 7). (B) Expression of P53-related mRNA in MM cells with CCT2 knockdown and overexpression (each cell line has its own control). (C) Detection of some protein levels (original western blot membranes are shown in Supplementary Document 8). (* P < 0.05, ** P < 0.01, **** P < 0.0001) Detection of P53 pathway genes and protein levels. (A) Expression of TP53 in newly diagnosed MM patients (original western blot membranes are shown in Supplementary Document 7). (B) Expression of P53-related mRNA in MM cells with CCT2 knockdown and overexpression (each cell line has its own control). (C) Detection of some protein levels (original western blot membranes are shown in Supplementary Document 8). (* P < 0.05, ** P < 0.01, **** P < 0.0001) Fig. 5Validation of the P53 pathway. (A) Compared with the control sh-CCT2 group, the proliferation of the MM group with sh-CCT2 after addition of PFT-α was significantly increased. (B) Apoptosis was significantly decreased in the PFT-α group. (C) The number of cells in the G1 phase was reduced in the PFT-α group. Changes in downstream molecules in the PFT-α group. (D) Changes in P53 pathway-related mRNA after addition of the P53 inhibitor PFT-α. (E) Changes in P53 pathway-related proteins after addition of the P53 inhibitor PFT-α(original western blot membranes are shown in Supplementary Document 9). (F) Schematic diagram of the interaction between CCT2 and the P53 pathway (this pathway mechanism diagram is based on previously reported literature). (* P < 0.05, ** P < 0.01, **** P < 0.0001) Validation of the P53 pathway. (A) Compared with the control sh-CCT2 group, the proliferation of the MM group with sh-CCT2 after addition of PFT-α was significantly increased. (B) Apoptosis was significantly decreased in the PFT-α group. (C) The number of cells in the G1 phase was reduced in the PFT-α group. Changes in downstream molecules in the PFT-α group. (D) Changes in P53 pathway-related mRNA after addition of the P53 inhibitor PFT-α. (E) Changes in P53 pathway-related proteins after addition of the P53 inhibitor PFT-α(original western blot membranes are shown in Supplementary Document 9). (F) Schematic diagram of the interaction between CCT2 and the P53 pathway (this pathway mechanism diagram is based on previously reported literature). (* P < 0.05, ** P < 0.01, **** P < 0.0001) Discussion Multiple myeloma (MM) is a hematologic malignancy that is difficult to cure5–8. Therefore, identifying new molecular targets and mechanisms for MM is crucial for patient treatment. In this study, we demonstrated that CCT2 is a gene responsible for regulating MM proliferation. When CCT2 is downregulated, it activates the p53 pathway, promoting apoptosis and cell cycle arrest, thereby inhibiting the proliferation of MM cells. As a component of the TRiC complex, the involvement of the CCT2 protein molecule in the protein folding process under ATP hydrolysis conditions has been confirmed by multiple studies24–26. Existing literature indicates that this molecule is significantly associated with malignant tumor proliferation, apoptosis regulation, and cell cycle disorders, and it can also serve as an indicator of poor prognosis16,17. This study selected multiple myeloma as the research subject and, based on bioinformatics techniques combined with clinical data correlation analysis, ultimately identified CCT2 as having potential research value. Data show that among multiple myeloma patient populations, the CCT2 gene is significantly overexpressed, and this expression pattern is clearly associated with poorer patient survival. Initial diagnostic specimen testing revealed high expression of CCT2 in bone marrow plasma cells of MM patients, with expression levels positively correlated with the proportion of plasma cells. Using lentiviral vector transfection technology to construct MM cell models and flow cytometry-based subcutaneous MM tumor formation assays, it was found that CCT2 plays an important role in regulating multiple biological processes, including MM cell proliferation, apoptosis, and cell cycle progression. In molecular-level studies, through in vitro cell experiments, the effects of CCT2 on MM cell proliferation, apoptosis, and cell cycle regulation have been found to be associated with the P53 pathway signaling. When CCT2 is downregulated, decreased expression levels are observed in BCL-2, MDM2, CDK2, and Cyclin E; conversely, the expression of BAX, FAS, Caspase 3, CHEK1, and P21 shows an increasing trend. Previous literature indicates that these factors are key components involved in apoptosis and cell cycle regulation within the P53 pathway18,20–22. Studies have shown that adding a P53 inhibitor to CCT2-knockdown MM cells enhances cell proliferation, accompanied by a decrease in apoptosis rate and a reduction in the proportion of cells in the G0/G1 phase. At this time, the expression levels of BCL-2 and MDM2 rebound, while those of BAX and CHEK1 correspondingly decrease. These findings suggest that MM cell growth is influenced by CCT2 through apoptosis and cell cycle arrest mediated by the P53 pathway. However, the specific interaction mechanism between CCT2 and P53, as well as their roles in the apoptosis and cell cycle regulatory network, require further investigation. Previous studies have shown that CCT2 plays an important role in protein folding and assembly as well as ATP hydrolysis30–32. According to prior research, CCT2 may regulate p53 activity by affecting the ATR/Chek1 pathway14,33,34; increased ATR phosphorylation activates CHEK1 kinase, which in turn activates p5320,35. However, this study did not directly verify the specific changes in phosphorylation of ATR, Chek1, and p53, so this mechanism requires further experimental confirmation. Meanwhile, MDM2, as a major negative regulator of p53, when expressed at lower levels, reduces p53 ubiquitination and degradation, leading to increased intracellular p5335,36. Under p53 activation, conformational changes in the cell surface apoptosis receptor FAS have been observed; similarly, the conformation of the Fas-associated death domain protein (FADD) also changes. An increase in Caspase-3 expression occurs simultaneously; the pro-apoptotic protein Bid is cleaved to form t-Bid. After t-Bid binds to the mitochondrial membrane, the activation of BAX is facilitated37–39. The inhibitory effect of BCL-2 on this process has been confirmed. When BCL-2 expression decreases, BAX inhibition is relieved; mitochondrial membrane permeabilization is enhanced, and cytochrome c release increases. Cytochrome c binds to Caspase-9 to form the apoptosome, leading to Caspase-3 activation40–42, thereby advancing the apoptosis process. Under p53 pathway activation, the expression level of the cell cycle inhibitor P21 increases; P21 negatively regulates Cyclin E/CDK2 expression, causing cell cycle arrest in the G1 phase43. The data analysis results of this study are consistent with these findings: after CCT2 knockdown, the p53 signaling pathway is activated, multiple myeloma (MM) cell proliferation is inhibited, accompanied by increased apoptosis and cell cycle arrest. This study has certain limitations in the clinical trial section, primarily due to an insufficient number of patient samples. This introduces a risk of selection bias, weakening the representativeness of the sample and thereby affecting the generalizability of the target population and the reliability of the results. Subsequent sample collection will continue, and follow-up evaluations will be conducted simultaneously. Further research in the areas of cell experiments and animal studies will also be actively pursued by our research team. Conclusion Through this study, we confirmed the oncogenic role and prognostic relevance of CCT2 in multiple myeloma (MM). Knockdown of CCT2 activates the p53 signaling pathway, inhibiting MM cell proliferation by accelerating apoptosis and inducing cell cycle arrest. The results of this study not only lay a theoretical foundation for elucidating the molecular mechanisms underlying MM disease progression but also may provide new directions for screening biomarkers and identifying potential therapeutic targets in clinical diagnosis and treatment. Future work will involve expanding the sample size and conducting multicenter validations to ensure the generalizability and reliability of the findings, ultimately offering new therapeutic strategies for MM patients. Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3 Supplementary Material 4 Supplementary Material 4 Supplementary Material 5 Supplementary Material 5 Supplementary Material 6 Supplementary Material 6 Supplementary Material 7 Supplementary Material 7 Supplementary Material 8 Supplementary Material 8 Supplementary Material 9 Supplementary Material 9 Supplementary Material 10 Supplementary Material 10 Supplementary Material 11 Supplementary Material 11